User:Marieyellow11/IPEX syndrome

SOURCES:

https://www.mdpi.com/2073-4425/12/3/323

https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/nyas.13011

https://onlinelibrary.wiley.com/doi/10.1002/eji.202149210

https://www.sciencedirect.com/science/article/abs/pii/S0301054609000238?via%3Dihub

https://www.sciencedirect.com/science/article/pii/S1673852720300084?via%3Dihub

https://www.embase.com/records?subaction=viewrecord&rid=12&page=1&id=L2005782355

Article Draft (original in bold, mine below) edit

Immunodysregulation polyendocrinopathy enteropathy X-linked (or IPEX) syndrome is a rare disease linked to the dysfunction of the gene encoding transcription factor forkhead box P3 (FOXP3), widely considered to be the master regulator of the regulatory T cell lineage.[1][2] It leads to the dysfunction of CD4+ regulatory T-cells and the subsequent autoimmunity.[3] The disorder is one of the autoimmune polyendocrine syndromes and manifests with autoimmune enteropathy, psoriasiform or eczematous dermatitis, nail dystrophy, autoimmune endocrinopathies, and autoimmune skin conditions such as alopecia universalis and bullous pemphigoid.[3][4] Management for IPEX has seen limited success in treating the syndrome by bone marrow transplantation.[5] edit

Immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome is a rare autoimmune disease. It is one of the autoimmune polyendocrine syndromes. Most often, IPEX presents with autoimmune enteropathy, dermatitis (eczema), and autoimmune endocrinopathy (most often Type 1 diabetes), but other presentations exist.[6]

IPEX is caused by mutations in the gene FOXP3, which encodes the transcription factor forkhead box P3 (FOXP3). FOXP3 is widely considered to be the master regulator of the regulatory T cell lineage.[7][8] FOXP3 mutations lead to the dysfunction of CD4+ regulatory T cells. In healthy people, regulatory T cells maintain immune homeostasis.[9] When there is a FOXP3 mutation, regulatory T cells do not function properly and cause autoimmunity.[10][11]

IPEX onset usually happens in infancy. If left untreated, it is usually fatal by the age of 2 or 3.[12][13] Treatment options are limited, but IPEX can be cured through a bone marrow transplant.[14]

Presentation edit

The most representative criterion for the diagnosis of IPEX syndrome is autoimmune enteropathy. The first symptoms of enteropathy begin at birth and they are characterized by diarrhea, vomiting, gastritis, ileus, and colitis. The second hallmark is type 1 diabetes (T1D) and the worst complication of it is destruction of the pancreas, confirmed by histological examinations. Dermatitis is the next sign and it can be presented in three forms: eczematiform (mainly atopic dermatitis), ichthyosiform, psoriasiform, or combinations of them. Other skin manifestations can include cheilitis, onychodystrophy and alopecia. Other atypical symptoms include: thyroid and renal dysfunction, reduced counts of thrombocytes and neutrophils, arthritis, splenomegaly, lymphadenopathy and infections.[15]

Classical Triad edit

The classical triad describes the three most common symptoms of IPEX syndrome: intractable diarrhea, type 1 diabetes (T1D), and eczema. These symptoms usually begin shortly after birth. Other symptoms include: thyroid disease, kidney dysfunction, hematologic abnormalities, frequent infections, autoimmune hemolytic anemia, and food allergies, among others.[16]

Endocrinopathy edit

The most common endocrinopathy involved in IPEX is type 1 diabetes. This can permanently damage the pancreas. Thyroid disorders are also common.[17]

Enteropathy edit

Another common symptom of IPEX is enteropathy. This can present in many different ways, but the most common is intractable diarrhea. Vomiting and gastritis are also common. Other manifestations include Celiac disease and ulcerative colitis.[18]

Skin Manifestations
Eczema
edit

The most common skin involvement is dermatitis. This may be eczematiform (mainly atopic dermatitis), ichthyosiform, psoriasiform, or a combination. Other skin manifestations include cheilitis, onychodystrophy, and alopecia.[19]

Dermatitis is the next sign and it can be presented in three forms: eczematiform (mainly atopic dermatitis), ichthyosiform, psoriasiform, or combinations of them. Other skin manifestations can include cheilitis, onychodystrophy and alopecia.

Family history of IPEX patients edit

IPEX patients are usually born with normal weight and length at term. Nevertheless, the first symptoms may present in the first days of life,[20] and some reported cases labeled newborns with intrauterine growth retardation and evidence of meconium in the amniotic fluid.[21] edit

Genetics edit

FOXP3 edit

Mutations in FOXP3 gene causing IPEX syndrome - known in the year 2012.

IPEX syndrome is inherited in males through the FOXP3 gene in an x-linked recessive pattern. FOXP3's cytogenetic location is Xp11.23.[1][2] The FOXP3 gene has 12 exons and its full reading open frame encodes 431 amino acids. FOXP3 is a member of the FKH family of transcription factors and contains a proline‐rich (PRR) amino‐terminal domain, central zinc finger (ZF) and leucine zipper (LZ) domains important for protein–protein interactions. It also has a carboxyl‐terminal FKH domain required for nuclear localization and DNA‐binding activity. In humans, exons 2 and 7 are spliced and excluded from the protein.[15]

Mutations edit

A large variety of mutations have been found, including single base substitutions, deletions, and splicing mutations. Data from 2018 describes over 70 mutations in FOXP3 gene leading to IPEX syndrome. This number has grown dramatically with new research.[22] For example, In 2010 there were only 20 mutations of FOXP3 known in the literature.[23] Some mutations, which cause FOXP3 expression to malfunction, lead to a defect in Treg production. Those patients do not have circulating CD4+/CD25+/FOXP3+ Treg cells. Reduced expression of FOXP3 has been described. These individuals may express normal levels of dysfunctional protein, which leads to mild symptoms later in life or during the neonatal period. Other individuals may have completely absent FOXP3 expression. In case of suspicion of IPEX syndrome patients should have genetic testing, even if FOXP31 T cells are present in the periphery.[24] A common location for mutation of FOXP3 leading to expression of malfunctioning protein is often localized in the DNA-binding domain called the forkhead domain. The mutation makes the truncated protein unable to bind its DNA binding site. This impairs its function concerning T regulatory lymphocytes development and functioning. The absence or dysfunction of regulatory T cells is the cause of autoimmune symptoms.[23] Data from 2018 describes over 70 mutations in FOXP3 gene leading to IPEX syndrome. Nonetheless, this number is still changing with new cases and discoveries coming.[22] For example, in 2010 there were only 20 mutations of FOXP3 known in the literature.[23]

FOXP3 pathways edit

FOXP3 can function as both a repressor and a trans‐activator of Treg cells depending on its interactions with other proteins. FOXP3 expression is characterised by controlling transcription, influencing epigenetic changes and post-transcriptional modifications. The N‐terminal repressor domain of FOXP3 can change transcription or epigenetic regulation of Treg cells. Transcriptional activity is altered through interactions between the N-terminal domain and Eos - which associates with CtBP1 and forms a corepressor complex. This complex binds the IL2 promoter and enables FOXP3 to repress IL2 transcription in Treg cells. FOXP3 forms complexes with histone deacetylase (HDAC)7, HDAC9, and the histone acetyl transferase TIP60, which alters epigenetic activity of Treg cells. The N‐terminal domain of FOXP3 can also antagonize the transcription factors RORγ and RORα, thereby inhibiting TH17 cell differentiation. FOXP3 is linked to TCR signaling by downstream transcription factors. All of these findings verify the importance of FOXP3 in the regulation of transcriptional activity/repression in Treg cells.[15] edit

Mechanism edit

This autoimmunity called IPEX is an attack from the body's own immune system against the body's own tissues and organs.[25] Early age onset of this disease in males causes severe enlargement of the secondary lymphoid organs, and insulin dependent diabetes[medical citation needed] This condition indicates the loss of CD4+ CD25+ T regulatory cells, and express the transcription factor Foxp3. Foxp3 decrease is a consequence of unchecked T cell activation, which is secondary to loss of regulatory T cells.[26] Causes of death include haemorrhage, sepsis, Intractable diarrhoea and diabetic complications[5] edit

Diagnosis edit

=== Early detection of the disease is crucial because mortality is on high level without treatment.[24] The diagnosis of immunodysregulation polyendocrinopathy enteropathy X-linked syndrome is consistent with the following criteria:[27][25]

  • Clinical triad
  • Family history
  • Laboratory findings: elevated serum concentration of IgE, eosinophilia, autoimmune anemia and decreased number of FOXP3 Treg cells.
  • Genetic testing: single-gene testing and multigene panel. ===

Treatment edit

===

Tacrolimus

In terms of treatment the following are done to manage the IPEX syndrome in those affected individuals (corticosteroids are the first treatment that is used):[25][28]


Individuals with IPEX will usually need supportive care in a hospital. Most common is nutritional treatment for enteropathy and insulin therapy for T1D. IPEX treatment tends to focus on managing symptoms, reducing autoimmunity, and/or treating secondary conditions. Usually, treatment will involve immunosuppression. Drugs used include:

Currently, the standard treatment for IPEX is a bone marrow transplant. If donor-recipient chimerism is achieved, individuals with IPEX can achieve complete remission.

Research History edit

In non-human research that has been conducted there is as well a special mouse model simulating the development and progression of the IPEX syndrome. The model mice are called "scurfy mice" and they have had 2 base pairs inserted within the Foxp3 gene. This leads to a frameshift mutation in Foxp3 gene and the expressed protein is truncated, causing functional deficiency of Treg cells. Consequently, autoreactive CD4+T cells and inflammatory cells are causing tissue damaging. Beside CD4+T cells to inflammation disorder contribute B cells by producing autoantibodies like antinuclear antibodies.[29] The mice had enlarged spleen and lymph nodes, redness in eyes, and skin abnormalities. The mice also had immunity problems and died after approximately 3 weeks.[22] edit

In 1982, Powel et al. published a case report of a family with 19 males who were affected by an X-linked syndrome with symptoms including polyendocrinopathy and diarrhea. The most common symptoms in this family were severe enteropathy, T1D, and dermatitis. Only 2 of the 19 affected males in the family survived past 3 years old. These individuals lived to 10 and 30 years old.[30] Powel's study is now widely considered the first documentation of IPEX.

Scurfy Mice edit

Scurfy is a type of model mouse used for immunology research. They have had 2 base pairs inserted within the Foxp3 gene. This leads to a frameshift mutation in Foxp3 gene and the expressed protein is truncated, causing functional deficiency of Treg cells. Then, autoreactive CD4+T cells and inflammatory cells cause tissue damage.[29] Scurfy mice have an enlarged spleen and lymph nodes, squinted red eyes, and scaly or "ruffled" skin. The mice also have immunity problems and tend to die approximately 3 weeks after birth.[22] From 2000 - 2001, multiple studies confirmed that IPEX is the human equivalent of scurfy mice and that the FOXP3 gene is responsible.[31]

See also edit

= edit

  1. ^ a b "IPEX syndrome". Genetics Home Reference. Retrieved 2017-04-16.
  2. ^ a b "FOXP3 gene". Genetics Home Reference. Retrieved 2017-04-16.
  3. ^ a b Rapini RP, Bolognia JL, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. p. 72. ISBN 978-1-4160-2999-1.
  4. ^ "Immunodysregulation, polyendocrinopathy and enteropathy X-linked | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Archived from the original on 2019-01-09. Retrieved 2017-04-16.
  5. ^ a b Wildin RS, Smyk-Pearson S, Filipovich AH (August 2002). "Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome". Journal of Medical Genetics. 39 (8): 537–45. doi:10.1136/jmg.39.8.537. PMC 1735203. PMID 12161590.
  6. ^ "Embase". www.embase.com. Retrieved 2023-04-04.
  7. ^ "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: MedlinePlus Genetics". medlineplus.gov. Retrieved 2023-04-04.
  8. ^ "FOXP3 gene: MedlinePlus Genetics". medlineplus.gov. Retrieved 2023-04-04.
  9. ^ Huang, Qianru; Liu, Xu; Zhang, Yujia; Huang, Jingyao; Li, Dan; Li, Bin (2020-01-20). "Molecular feature and therapeutic perspectives of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome". Journal of Genetics and Genomics. 47 (1): 17–26. doi:10.1016/j.jgg.2019.11.011. ISSN 1673-8527.
  10. ^ Huang, Qianru; Liu, Xu; Zhang, Yujia; Huang, Jingyao; Li, Dan; Li, Bin (2020-01-20). "Molecular feature and therapeutic perspectives of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome". Journal of Genetics and Genomics. 47 (1): 17–26. doi:10.1016/j.jgg.2019.11.011. ISSN 1673-8527.
  11. ^ Bacchetta, Rosa; Barzaghi, Federica; Roncarolo, Maria-Grazia (2018-04). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation: IPEX syndrome and FOXP3". Annals of the New York Academy of Sciences. 1417 (1): 5–22. doi:10.1111/nyas.13011. {{cite journal}}: Check date values in: |date= (help)
  12. ^ Ben-Skowronek, Iwona (2021-03). "IPEX Syndrome: Genetics and Treatment Options". Genes. 12 (3): 323. doi:10.3390/genes12030323. ISSN 2073-4425. {{cite journal}}: Check date values in: |date= (help)CS1 maint: unflagged free DOI (link)
  13. ^ Bacchetta, Rosa; Barzaghi, Federica; Roncarolo, Maria-Grazia (2018-04). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation: IPEX syndrome and FOXP3". Annals of the New York Academy of Sciences. 1417 (1): 5–22. doi:10.1111/nyas.13011. {{cite journal}}: Check date values in: |date= (help)
  14. ^ Ben-Skowronek, Iwona (2021-03). "IPEX Syndrome: Genetics and Treatment Options". Genes. 12 (3): 323. doi:10.3390/genes12030323. ISSN 2073-4425. {{cite journal}}: Check date values in: |date= (help)CS1 maint: unflagged free DOI (link)
  15. ^ a b c Bacchetta, Rosa; Barzaghi, Federica; Roncarolo, Maria-Grazia (2018). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation". Annals of the New York Academy of Sciences. 1417 (1): 5–22. Bibcode:2018NYASA1417....5B. doi:10.1111/nyas.13011. ISSN 1749-6632. PMID 26918796.
  16. ^ Park JH, Lee KH, Jeon B, Ochs HD, Lee JS, Gee HY, et al. (June 2020). "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review". Autoimmunity Reviews. 19 (6): 102526. doi:10.1016/j.autrev.2020.102526. PMID 32234571. S2CID 214768010.
  17. ^ Park, Jae Hyon; Lee, Keum Hwa; Jeon, Bokyoung; Ochs, Hans D.; Lee, Joon Suk; Gee, Heon Yung; Seo, Seeun; Geum, Dongil; Piccirillo, Ciriaco A.; Eisenhut, Michael; van der Vliet, Hans J.; Lee, Jiwon M.; Kronbichler, Andreas; Ko, Younhee; Shin, Jae Il (2020-06-01). "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review". Autoimmunity Reviews. 19 (6): 102526. doi:10.1016/j.autrev.2020.102526. ISSN 1568-9972.
  18. ^ Park, Jae Hyon; Lee, Keum Hwa; Jeon, Bokyoung; Ochs, Hans D.; Lee, Joon Suk; Gee, Heon Yung; Seo, Seeun; Geum, Dongil; Piccirillo, Ciriaco A.; Eisenhut, Michael; van der Vliet, Hans J.; Lee, Jiwon M.; Kronbichler, Andreas; Ko, Younhee; Shin, Jae Il (2020-06-01). "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review". Autoimmunity Reviews. 19 (6): 102526. doi:10.1016/j.autrev.2020.102526. ISSN 1568-9972.
  19. ^ Park, Jae Hyon; Lee, Keum Hwa; Jeon, Bokyoung; Ochs, Hans D.; Lee, Joon Suk; Gee, Heon Yung; Seo, Seeun; Geum, Dongil; Piccirillo, Ciriaco A.; Eisenhut, Michael; van der Vliet, Hans J.; Lee, Jiwon M.; Kronbichler, Andreas; Ko, Younhee; Shin, Jae Il (2020-06-01). "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review". Autoimmunity Reviews. 19 (6): 102526. doi:10.1016/j.autrev.2020.102526. ISSN 1568-9972.
  20. ^ Barzaghi F, Passerini L, Bacchetta R (2012). "Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity". Frontiers in Immunology. 3: 211. doi:10.3389/fimmu.2012.00211. PMC 3459184. PMID 23060872.
  21. ^ Xavier-da-Silva MM, Moreira-Filho CA, Suzuki E, Patricio F, Coutinho A, Carneiro-Sampaio M (February 2015). "Fetal-onset IPEX: report of two families and review of literature". Clinical Immunology. 156 (2): 131–40. doi:10.1016/j.clim.2014.12.007. PMID 25546394.
  22. ^ a b c d Bacchetta R, Barzaghi F, Roncarolo MG (April 2018). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation". Annals of the New York Academy of Sciences. 1417 (1): 5–22. Bibcode:2018NYASA1417....5B. doi:10.1111/nyas.13011. PMID 26918796.
  23. ^ a b c Michels AW, Gottlieb PA (May 2010). "Autoimmune polyglandular syndromes". Nature Reviews. Endocrinology. 6 (5): 270–7. doi:10.1038/nrendo.2010.40. PMID 20309000. S2CID 20395564.
  24. ^ a b Kitcharoensakkul, Maleewan; Cooper, Megan A. (2020-01-01), Rose, Noel R.; Mackay, Ian R. (eds.), "Chapter 28 - Autoimmunity in Primary Immunodeficiency Disorders", The Autoimmune Diseases (Sixth Edition), Academic Press, pp. 513–532, doi:10.1016/b978-0-12-812102-3.00028-2, ISBN 978-0-12-812102-3, S2CID 208377306, retrieved 2021-01-29
  25. ^ a b c Hannibal M, Torgerson T (1993-01-01). "IPEX Syndrome". In RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, Bird TD, Ledbetter N, Mefford H (eds.). GeneReviews. Seattle (WA): University of Washington, Seattle. PMID 20301297.update 2011
  26. ^ Verbsky JW, Chatila TA (December 2013). "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases". Current Opinion in Pediatrics. 25 (6): 708–14. doi:10.1097/MOP.0000000000000029. PMC 4047515. PMID 24240290.
  27. ^ "Orphanet: Immune dysregulation polyendocrinopathy enteropathy X linked syndrome". www.orpha.net. Retrieved 2017-04-18.
  28. ^ Eisenbarth GS (2010-12-13). Immunoendocrinology: Scientific and Clinical Aspects. Springer Science & Business Media. pp. 129–138. ISBN 9781603274784.
  29. ^ a b Yilmaz OK, Haeberle S, Zhang M, Fritzler MJ, Enk AH, Hadaschik EN (2019). "Scurfy Mice Develop Features of Connective Tissue Disease Overlap Syndrome and Mixed Connective Tissue Disease in the Absence of Regulatory T Cells". Frontiers in Immunology. 10: 881. doi:10.3389/fimmu.2019.00881. PMC 6491778. PMID 31068947.
  30. ^ Powell, Berkley R.; Buist, Neil R.M.; Stenzel, Peter (1982-05). "An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy". The Journal of Pediatrics. 100 (5): 731–737. doi:10.1016/s0022-3476(82)80573-8. ISSN 0022-3476. {{cite journal}}: Check date values in: |date= (help)
  31. ^ Bacchetta, Rosa; Barzaghi, Federica; Roncarolo, Maria-Grazia (2018-04). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation: IPEX syndrome and FOXP3". Annals of the New York Academy of Sciences. 1417 (1): 5–22. doi:10.1111/nyas.13011. {{cite journal}}: Check date values in: |date= (help)